Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection
Journal of the American College of Cardiology, 2012•jacc.org
Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger
that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in
the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase
(PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic
approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin
cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative …
that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in
the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase
(PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic
approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin
cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative …
Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit.
jacc.org